Major recommendations for vaccinations for hematopoietic stem cell transplant (HSCT) recipients, including both allogeneic and autologous recipients.For these guidelines, HSCT recipients are presumed immunocompetent at ≈ 24 months after HSCT if they are not on immunosuppressive therapy and do not have graft-versus-host-disease (GHVD).
| . | Time after HSCT . | . | ||
|---|---|---|---|---|
| Vaccine or toxoid . | 12 months . | 14 months . | 24 months . | Rating . |
| Inactivated vaccine or toxoid | ||||
| Diphtheria, tetanus, pertussis | Diphtheria toxoid-tetanus | DTP | DTP or DT | BIII |
| Children aged < 7 years | Toxoid-pertussis vaccine (DTP) or diphtheria toxoid-tetanus toxoid (DT) | |||
| Children aged ≥ 7 years | Tetanus-diphtheria toxoid (Td) | Td | Td | BII |
| Haemophilus influenza type b (Hib) conjugate | Hib conjugate | Hib conjugate | Hib conjugate | BII |
| Hepatitis (HepB) | HepB | HepB | HepB | BIII |
| 23-valent pneumococcal polysaccharide (PPV23) | PPV23 | — | PPV23 | BIII |
| Influenza | Lifelong, seasonal administration, beginning before HSCT and resuming at ≥ 6 months after HSCT | BII | ||
| Inactivated Polio (IPV) | IPV | IPV | IPV | BII |
| Life-attenuated vaccine | ||||
| Measles-mumps-rubella (MMR) | — | — | MMR | BIII |
| Varicella vaccine | Contraindicated for HSCT recipients | EIII | ||
| Rotavirus vaccine | Not recommended for any person in the United States | EII | ||
| . | Time after HSCT . | . | ||
|---|---|---|---|---|
| Vaccine or toxoid . | 12 months . | 14 months . | 24 months . | Rating . |
| Inactivated vaccine or toxoid | ||||
| Diphtheria, tetanus, pertussis | Diphtheria toxoid-tetanus | DTP | DTP or DT | BIII |
| Children aged < 7 years | Toxoid-pertussis vaccine (DTP) or diphtheria toxoid-tetanus toxoid (DT) | |||
| Children aged ≥ 7 years | Tetanus-diphtheria toxoid (Td) | Td | Td | BII |
| Haemophilus influenza type b (Hib) conjugate | Hib conjugate | Hib conjugate | Hib conjugate | BII |
| Hepatitis (HepB) | HepB | HepB | HepB | BIII |
| 23-valent pneumococcal polysaccharide (PPV23) | PPV23 | — | PPV23 | BIII |
| Influenza | Lifelong, seasonal administration, beginning before HSCT and resuming at ≥ 6 months after HSCT | BII | ||
| Inactivated Polio (IPV) | IPV | IPV | IPV | BII |
| Life-attenuated vaccine | ||||
| Measles-mumps-rubella (MMR) | — | — | MMR | BIII |
| Varicella vaccine | Contraindicated for HSCT recipients | EIII | ||
| Rotavirus vaccine | Not recommended for any person in the United States | EII | ||